Federated Hermes’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$2.67M Buy
298,201
+113,297
+61% +$1.02M 0.01% 868
2025
Q1
$1.39M Buy
184,904
+16,947
+10% +$127K ﹤0.01% 1026
2024
Q4
$1.26M Buy
167,957
+56,930
+51% +$428K ﹤0.01% 1044
2024
Q3
$844K Buy
+111,027
New +$844K ﹤0.01% 1180
2022
Q2
Sell
-348
Closed -$6K 2149
2022
Q1
$6K Sell
348
-47,893
-99% -$826K ﹤0.01% 1933
2021
Q4
$668K Sell
48,241
-819,896
-94% -$11.4M ﹤0.01% 1401
2021
Q3
$12.5M Buy
868,137
+121,166
+16% +$1.74M 0.02% 592
2021
Q2
$11.8M Buy
746,971
+722,057
+2,898% +$11.4M 0.02% 602
2021
Q1
$253K Buy
24,914
+24,750
+15,091% +$251K ﹤0.01% 1669
2020
Q4
$1K Buy
+164
New +$1K ﹤0.01% 2156
2019
Q4
Sell
-331,172
Closed -$949K 2211
2019
Q3
$949K Sell
331,172
-277,144
-46% -$794K ﹤0.01% 1287
2019
Q2
$2.31M Sell
608,316
-171,090
-22% -$649K 0.01% 1017
2019
Q1
$6.34M Buy
779,406
+343,269
+79% +$2.79M 0.02% 711
2018
Q4
$3.52M Buy
436,137
+434,756
+31,481% +$3.51M 0.01% 840
2018
Q3
$11K Buy
+1,381
New +$11K ﹤0.01% 1937
2017
Q3
Sell
-69,320
Closed -$385K 2136
2017
Q2
$385K Sell
69,320
-182,740
-72% -$1.01M ﹤0.01% 1432
2017
Q1
$2.12M Buy
252,060
+168,225
+201% +$1.41M 0.01% 884
2016
Q4
$531K Buy
83,835
+2,983
+4% +$18.9K ﹤0.01% 1282
2016
Q3
$357K Sell
80,852
-23,722
-23% -$105K ﹤0.01% 1373
2016
Q2
$297K Buy
+104,574
New +$297K ﹤0.01% 1405
2016
Q1
Sell
-1,000
Closed -$10K 2100
2015
Q4
$10K Buy
+1,000
New +$10K ﹤0.01% 1790